用于胃癌患者早期检测的液体活检特征
本研究分三步纳入2141例受试者(含888例胃癌、158例慢性萎缩性胃炎、193例肠上皮化生、501例健康供者及401例其他消化道肿瘤),开发并验证基于血液细胞外囊泡的长链非编码RNA特征GClnc1用于胃癌早期检测。发现阶段GClnc1在组织和循环细胞外囊泡中均上调,对早期胃癌(I/II期)的AUC为0.9369(95%CI 0.9073-0.9664),并在两个外部验证队列(西安队列AUC 0.8839,95%CI 0.8336-0.9342;北京队列AUC 0.9018,95%CI 0.8597-0.9439)中得到确认。
要点
- 细胞外囊泡来源的GClnc1对早期胃癌(I/II期)的AUC为0.9369(95%CI 0.9073-0.9664)。
- 两个外部验证队列的AUC分别为0.8839(95%CI 0.8336-0.9342)和0.9018(95%CI 0.8597-0.9439)。
- GClnc1能区分早期胃癌与癌前病变及传统胃肠肿瘤标志物阴性的胃癌。
核心结论
- 细胞外囊泡来源的GClnc1可作为胃癌早期检测的循环生物标志物,为根治性手术和改善生存结局提供机会。
研究设计与样本
- 本研究为三步研究,纳入2141例受试者,包括888例胃癌、158例慢性萎缩性胃炎、193例肠上皮化生、501例健康供者和401例其他消化道肿瘤。
- 发现阶段采用转录组分析I期胃癌组织样本的长链非编码RNA谱,并通过训练队列(n=554)、两个外部验证队列(n=429和n=504)及一个补充队列(n=69)识别和验证细胞外囊泡来源的长链非编码RNA特征。
主要发现
- 发现阶段,GClnc1在组织和循环细胞外囊泡样本中均上调,对早期胃癌(I/II期)的AUC为0.9369(95%CI 0.9073-0.9664)。
- 西安外部验证队列的AUC为0.8839(95%CI 0.8336-0.9342),北京外部验证队列的AUC为0.9018(95%CI 0.8597-0.9439)。
- 细胞外囊泡来源的GClnc1能稳健区分早期胃癌与癌前病变(慢性萎缩性胃炎和肠上皮化生)以及传统胃肠肿瘤标志物(CEA、CA72-4和CA19-9)阴性的胃癌。
- 术后血浆和其他消化道肿瘤血浆样本中该生物标志物水平较低,表明其对胃癌具有特异性。
关键数值与推荐
- GClnc1对早期胃癌(I/II期)的AUC为0.9369(95%CI 0.9073-0.9664)。
- 西安队列的AUC为0.8839(95%CI 0.8336-0.9342),北京队列的AUC为0.9018(95%CI 0.8597-0.9439)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improving prognosis of GC are necessary. The present study is to develop a blood-based long noncoding RNA (LR) signature for the early-detection of GC. METHODS: The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastrointestinal cancers. The LR profile of stage I GC tissue samples were analyzed using transcriptomic profiling in discovery phase. The extracellular vesicle (EV)-derived LR signature was identified with a training cohort (n = 554) and validated with 2 external cohorts (n = 429 and n = 504) and a supplemental cohort (n = 69). RESULTS: In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) for early-stage GC (stage I/II). The diagnostic performance of this biomarker was further confirmed in 2 external validation cohorts (Xi'an cohort, AUC: 0.8839; 95% CI: 0.8336-0.9342; Beijing cohort, AUC: 0.9018; 95% CI: 0.8597-0.9439). Moreover, EV-derived GClnc1 robustly distinguished early-stage GC from precancerous lesions (chronic atrophic gastritis and intestinal metaplasia) and GC with negative traditional gastrointestinal biomarkers (CEA, CA72-4, and CA19-9). The low levels of this biomarker in postsurgery and other gastrointestinal tumor plasma samples indicated its GC specificity. CONCLUSIONS: EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes.
引用
- Guo X, Peng Y, Song Q, et al. A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients. Gastroenterology. 2023. PMID: 36894035. doi:10.1053/j.gastro.2023.02.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。